Acurx Pharmaceuticals, Inc. Common Stock
ACXP XNASAbout Acurx Pharmaceuticals, Inc. Common Stock
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0 | $-1,680,982 | $-0.62 |
| FY 2025 | $0 | $-7,966,538 | $-5.32 |
| Q3 2025 | $0 | $-1,992,790 | $-1.23 |
| Q2 2025 | $0 | $-2,246,279 | $-1.89 |
Earnings & Analyst Ratings
TickerDaily Coverage
Get ACXP Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Acurx Pharmaceuticals, Inc. Common Stock.